A5103245475- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Asthma and respiratory diseases
- Pharmacological Effects and Assays
- Statistical Methods in Clinical Trials
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Inhalation and Respiratory Drug Delivery
- Receptor Mechanisms and Signaling
- Pharmaceutical studies and practices
- Advanced Causal Inference Techniques
- Adipose Tissue and Metabolism
- Healthcare Policy and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Renal cell carcinoma treatment
- Advanced Drug Delivery Systems
- Breast Cancer Treatment Studies
- Patient-Provider Communication in Healthcare
- Eosinophilic Disorders and Syndromes
- Neonatal Respiratory Health Research
Adelphi Group (United Kingdom)
2018-2025
Adelphi Laboratory Center
2021-2022
AstraZeneca (United Kingdom)
2007-2016
National Taiwan University Hospital
2016
AstraZeneca (United States)
2007
Purpose Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for prediction outcome from third-generation EGFR-TKI, osimertinib. Methods Plasma was collected all patients in the first-in-man study Patients who were included had acquired EGFR-TKI and evidence common...
In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; ≥10 mutations/megabase).To evaluate patient-reported outcomes (PROs) this population.Disease-related symptoms general health status were assessed using validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) EQ-5D,...
In CheckMate 743 (NCT02899299), nivolumab + ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma (MPM). We present patient-reported outcomes (PROs).Patients (N = 605) were randomized to or chemotherapy. Changes disease-related symptom burden and health-related quality of life (HRQoL) evaluated descriptively using the Lung Cancer Symptom Scale (LCSS)-Mesothelioma (Meso) average index (ASBI), LCSS-Meso 3-item global (3-IGI), 3-level...
Abstract Background Patients with refractory Mycobacterium avium complex lung disease (rMACLD) represent a difficult to treat population, who have not achieved culture conversion (CC) despite prolonged treatment multidrug antibacterial regimen (MDR). In the CONVERT trial, amikacin liposome inhalation suspension (ALIS) + MDR resulted in higher CC rates than alone during first 6 months of (29% vs 9%) patients that had positive cultures on for at least months. Adverse events (AEs) following...
Since 2021, the Danish Medicines Council recommends use of EQ-5D-5L value set when estimating utilities. The aim this research was to develop and validate an algorithm that can accurately predict mean utilities based on published UK EQ-5D-3L study design incorporated a secondary analysis patient-level utility index scores from 11 oncology clinical trials. responses were mapped with van Hout Shaw preferred mapping algorithm. Model fitting internal cross-validation completed pooled dataset...
In the phase 3 CheckMate 76 K trial, adjuvant nivolumab significantly improved recurrence-free survival and distant metastasis-free versus placebo in patients with resected stage IIB/C melanoma. We report patient-reported outcomes from K. Change baseline to week 53 health-related quality of life (HRQoL), as measured using EORTC QLQ-C30 EQ-5D-5L utility index visual analog scale (VAS), was compared between treatment groups linear mixed-effect models. Time confirmed deterioration (TTCD) HRQoL...
The platelet P2Y12 receptor is the target of clopidogrel therapy, which has been shown to reduce thromboembolic complications atherosclerotic disease but limitations in terms variability response and irreversibility effect. This also a for ticagrelor (AZD6140), first reversibly binding oral antagonist that does not require metabolic activation yields more consistent inhibition aggregation than therapy. Single nucleotide polymorphisms (SNPs) have described gene this (P2RY12), some associated...
Background In CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus (4 in patients metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years). Methods (N = 719) randomised 1:1 to or alone, disease-related symptom burden health-related quality of...
In ASCEMBL, an open-label, randomized Phase 3 study, asciminib demonstrated superior efficacy and better safety profile compared with bosutinib in patients chronic myeloid leukemia phase (CML-CP) previously treated ≥2 tyrosine kinase inhibitors. Health-related quality of life (HRQOL) reported by is key to understanding the benefit impact treatment on patients' lives, becoming increasingly important as expectancy CML-CP increases require long-term treatment. completed questionnaires assess...
Summary In drug development, we ask ourselves which population, endpoint and treatment comparison should be investigated. this context, also debate what matters most to the different stakeholders that are involved in clinical for example, patients, physicians, regulators payers. With publication of draft ICH E9 addendum on estimands 2017, now have a common framework language discuss such questions an informed transparent way. This has led estimand discussion being key element study including...
4535 Background: NIVO IV has improved outcomes in multiple tumor types. Evolving treatment paradigms have created a need for administration options that address burden and improve efficiencies of healthcare systems. In phase 1/2 study (CheckMate 8KX), pts were highly satisfied with SC preferred it over [Lonardi et al, ESMO 2022; Lonardi SITC 2023]. CheckMate 67T (NCT04810078) is multicenter, randomized, open-label, 3 demonstrated pharmacokinetic objective response rate noninferiority vs...
Abstract Background Evidence suggests that variation in the length of poly-C repeat 3′ untranslated region (3′UTR) β 2 -adrenergic receptor gene ( ADRB2 ) may contribute to interindividual β-agonist response. However, methodology previous studies limited assessment effect sequence context length. The objectives this study were design a novel genotyping method fully characterize 3′UTR asthma patients treated with inhaled corticosteroid and long-acting agonist (ICS/LABA) combination therapy,...
Abstract Background Breast cancer is one of the most common cancers in women. Patient-reported outcome measures are used to evaluate patients’ health-related quality life clinical breast studies. This study evaluated structure, validity, reliability, and responsiveness National Comprehensive Cancer Network-Functional Assessment Therapy-Breast Symptom Index (NFBSI-16) subscales a trial featuring patients with advanced/metastatic (aBC), estimated NFBSI-16 meaningful change thresholds. Methods...